Q4 Revenue Growth and EPS Beat
Fourth quarter revenue of $704M, up 7% year-over-year, and non-GAAP EPS of $0.71, which exceeded prior guidance of $0.62–$0.68.
Sequential Margin and Operating Leverage Improvement
Q4 non-GAAP gross margin of 10.6% (up 50 bps sequentially and 20 bps YoY) and non-GAAP operating margin of 5.5% (up 70 bps sequentially and 40 bps YoY), demonstrating leverage as revenue improved.
Full-Year Earnings Growth and Stable Revenue
Fiscal 2025 revenue of $2.66B was roughly flat versus prior year, while non-GAAP EPS grew 5% to $2.40, marking the fifth consecutive year of bottom-line performance outpacing the top line.
Strong Sector Performers — A&D, Medical, AC&C
Aerospace & Defense: Q4 +7% sequential, +17% YoY (FY +19%); Medical: Q4 +14% sequential, +23% YoY (FY +7%); AC & C: Q4 rebound +22% sequential, +27% YoY, with momentum into AI-related ramps.
Bookings Momentum and Targeted Investments
Meaningful bookings across space, MedTech, and enterprise AI; company investing in global precision footprint including a fourth Penang facility (to be completed Q2, operational Q3) and production equipment aligned to new wins.
Cash Generation and Improved Working Capital
Q4 operating cash flow of $59M and free cash flow of $48M; FY free cash flow $85M; net cash positive $111M, cash balance $322M (up $36M sequentially); cash conversion cycle improved to 67 days (down 10 days sequential / 22 days YoY).
Shareholder Returns and Capital Allocation
Distributed $24M in dividends and repurchased $27M in stock during the year with $123M remaining under repurchase authorization; continued focus on dividend and share repurchases while investing for growth.